Volume 9, Number 1:1-109;2019
American Journal of Nuclear Medicine and Molecular Imaging


Rozh H Al-Mashhadi, Jacob F Bentzon, Lars P Tolbod: Tissue volume and activity mapping using total intensity projection of PET/CT images. Am J Nucl Med Mol Imaging 2019;9(1):1-11. (Abstract ajnmmi0087540, Full text, PDF).

Irina Velikyan, Philip Schweighöfer, Joachim Feldwisch, Johanna Seemann, Fredrik Y Frejd, Henrik Lindman, Jens Sörensen: Diagnostic HER2-binding radiopharmaceutical, [68Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. Am J Nucl Med Mol Imaging 2019;9(1):12-23. (Abstract ajnmmi0090104, Full text, PDF).

Rustain Morgan, Bennett B Chin, Ryan Lanning: Feasibility of rapid integrated radiation therapy planning with follow-up FDG PET/CT to improve overall treatment assessment in head and neck cancer. Am J Nucl Med Mol Imaging 2019;9(1):24-29. (Abstract ajnmmi0090121, Full text, PDF).

Ashutosh Dash, Rubel Chakravarty: Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands. Am J Nucl Med Mol Imaging 2019;9(1):30-66. (Abstract ajnmmi0086228, Full text, PDF).

Ana de la Fuente, Stefan Kramer, Nicole Mohr, Stefanie Pektor, Benedikt Klasen, Nicole Bausbacher, Matthias Miederer, Rudolf Zentel, Frank Rösch: 68Ga[Ga]-, 111In[In]-oxine: a novel strategy of in situ radiolabeling of HPMA-based micelles. Am J Nucl Med Mol Imaging 2019;9(1):67-83. (Abstract ajnmmi0089394, Full text, PDF).

Rikke J Petersen, Nick S Nielsen, Helle H Johannesen, Adam E Hansen, Sofie Jespersen, Caroline J Arnbjerg, Johan Löfgren, Mette S Kjær, Mette R Clausen, Andreas Kjær, Susanne D Nielsen, Barbara M Fischer: PET/DW-MRI for evaluating treatment in chronic hepatitis C patients. Am J Nucl Med Mol Imaging 2019;9(1):84-92. (Abstract ajnmmi0089689, Full text, PDF).

Jadith Ziegler, Michelle Zalles, Nataliya Smith, Debra Saunders, Megan Lerner, Kar-Ming Fung, Maulin Patel, Jonathan D Wren, Florea Lupu, James Battiste, Rheal A Towner: Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment. Am J Nucl Med Mol Imaging 2019;9(1):93-109. (Abstract ajnmmi0089220, Full text, PDF).
AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA